Forty Seven is a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer. By harnessing macrophages, Co.'s primary product candidate, 5F9, can transform the treatment of cancer. In addition, Co. has two additional product candidates in preclinical development; FSI-189 an anti- SIRPa antibody and FSI-174 an anti-cKIT antibody. Co.'s primary product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. We show 7 historical shares outstanding datapoints in our FTSV shares outstanding history coverage, used to compute FTSV market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing FTSV market cap history over the course of time is important for investors
interested in comparing FTSV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of FTSV versus a peer is one thing; comparing
FTSV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like FTSV can fluctuate over the course of history.
With this page we aim to empower investors researching FTSV by allowing them to research the FTSV market cap history. |
Free FTSV Email Alerts:
Video: The Importance of Market Cap
